Weighing In On DPP-IV Inhibitors: Galvus, Januvia Both Highlight Weight Profiles

Data presented on the competing dipeptidyl peptidase IV inhibitors from Novartis and Merck at the American Diabetes Association similarly tout weight loss and other side effect advantages versus standard type 2 diabetes drugs.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet